Influence of Nevirapine on HCV Viral Load
Not Applicable
- Conditions
- HCV Infection.HCV Viral Load.
- Interventions
- Registration Number
- NCT01277627
- Lead Sponsor
- Valme University Hospital
- Brief Summary
Nevirapine-based antiretroviral therapy is associated with lower plasma HCV viral load in HIV/HCV-coinfected individuals.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- HIV infection.
- Older than 18 years.
- Chronic hepatitis C.
- Undetectable HIV viral load during one year before starting study.
- To have not received HCV therapy during one year before starting study.
- To have not started efavirenz or protease inhibitors o nucleoside analogs during 6 months before starting study.
- Non contraindications for drugs included in this study.
- To change an antiretroviral regimen including efavirenz or protease inhibitors by nevirapine due to side effects, interactions or pregnancy (NVP group)
- To continue with a antiretroviral regimen including efavirenz or protease inhibitors (non-NVP group)
Both groups will be matched according to these variables:
- Liver stiffness.
- HCV genotype.
- Hospital.
- Time from starting antiretroviral therapy.
- Previous third drug (EFV or PI) to introduction of NVP.
Exclusion Criteria
- HCV therapy during follow-up
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Nevirapine efavirenz, protease inhibitors - Non-nevirapine Nevirapine - Non-nevirapine efavirenz, protease inhibitors - Nevirapine Nevirapine -
- Primary Outcome Measures
Name Time Method Changes in HCV viral load 48 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Valme University Hospital
🇪🇸Seville, Spain